Brainstorm Cell Stock
€2.74
Your prediction
Brainstorm Cell Stock
Brainstorm Cell Therapeutics Inc. (Symbol: BCLI) is a biotechnology company specializing in the development of innovative adult stem cell therapies for central nervous system (CNS) diseases and disorders. Headquartered in New York, the company is dedicated to leveraging its proprietary NurOwn platform, which uses autologous, patient-derived cells to treat neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). By enhancing the cells' ability to secrete neurotrophic factors (NTFs) that support nerve cells' growth, survival, and function, Brainstorm Cell is at the forefront of clinical research to address the unmet need for therapies in this rapidly evolving field. As a publicly traded company, BCLI is listed on the Nasdaq stock exchange, offering prospective investors a unique opportunity to invest in a pioneering biotech company aiming to transform the lives of millions living with neurodegenerative diseases.
Pros and Cons of Brainstorm Cell in the next few years
Pros
Cons
Performance of Brainstorm Cell vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Brainstorm Cell | -0.720% | -0.725% | -0.725% | 1.182% | 93.230% | -63.467% | - |
| Concert Pharmaceuticals Inc. | 0.180% | 0.000% | 0.000% | - | 56.305% | - | - |
| Sorrento Therapeutics Inc. | - | 0.000% | 0.000% | -82.687% | -65.296% | -91.811% | - |
| Atara Biotherapeutics Inc. | 3.530% | -12.306% | -40.812% | -67.855% | -51.398% | -83.083% | - |
Comments
